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Abstract – An in vitro model that can realistically and 
inexpensively predict human response to various drug 
administration and toxic chemical exposure is needed. By 
fabricating a microscale 3D tissue analog consisting of an array 
of channels and tissue-embedded chambers, we can selectively 
biomimic different mammalian tissues for a multitude of 
applications, foremost among them experimental pharmaceutical 
screening for efficacy and toxicity. Our model may be envisioned 
as an important adjunct for assessing the beneficial and 
detrimental effects of novel drugs upon navigating a given 
metabolic pathway. Most exemplary, assessing the therapeutic or 
toxic effects of a drug on any cell type in vitro may be 
investigated in the presence of microencapsulated liver cells to 
take into account the liver-dependent metabolic modification of 
the candidate drug. Future functional studies will also be 
conducted for drug therapeutic benefit or toxicity evaluation at a 
downstream tissue chamber housing a target soft parenchymal 
tissue to form a multi-compartment tissue chamber. 
 
I.   INTRODUCTION 
 
Even today, macroscale animal testing endures as the 
prevailing model in the evaluation of toxicological and 
pharmacological profiles of chemicals and therapeutic agents. 
Accordingly, much of the inertia to extrapolate human 
response to drugs or chemicals from traditional in vitro culture 
systems derives from the belief that traditional in vitro culture 
systems do not accurately recapitulate the complex physiology 
of living organisms. While such static cell-based assays may 
indeed fail, its shortcomings in predicting relevant drug data 
may be less ascribed to chemistry and appreciably more to the 
failure to accurately simulate a drug’s navigational coursing 
through the body’s complex organs. That is, in order for a 
micro-scale in vitro system to serve as a human surrogate for 
drug analysis, it must adhere stringently to a physiologically-
based pharmokinetic (PBPK) model. Therefore, we can 
conceive and fabricate a stamp-sized tissue-on-a-chip 
microfluidic device which, with great fidelity, replicates an 
experimental drug’s sequential passage of being broken down 
by the liver, absorbed by the intestines, and held onto by fat.   
The general scope of this research centers upon the 
science of computer-aided tissue engineering (CATE) – an 
overarching field that encompasses computer-aided design 
(CAD), automated layered manufacturing techniques such as 
solid freeform fabrication (SFF), tissue engineering, and 
regenerative medicine [1]. Now, tissue engineering 
researchers have begun experimenting with syringe-based, 
layered manufacturing for tissue engineering – the distinct 
advantage being that these systems are adepth at handling and 
maintaining biological materials at physiologically relevant 
conditions [2,3,4,5]. Our process uniquely invokes a multi-
nozzle, heterogeneous material deposition system integrated 
within a CAD environment while operating along a three-
dimensional axis. The heterogeneous cell/material deposition 
capability of our process is amenable to the creation of 
composite, “smart” tissue constructs optimized for functional 
cellular development and potential organ morphogenesis with 
concomitant coculture of cells in a more biologically natural 
distribution [6]. For the specific application of experimental 
drug/chemical testing and toxicology, our process can bioprint 
three-dimensional tissue constructs to interface with 
microfluidic microanalytical devices to assess the  
pharmacokinetic predictive relevancy. 
Though other research groups have developed similar 
devices on a microscale, the novelty of our approach lies in 
combining the microfluidic device with 3-dimensional tissue 
models, as opposed to 2-dimensional cell cultures [7,8]. By 
utilizing our bioprinting methods, the creation of highly 
reproducible 3-D tissue models integrated with the tissue 
chambers of the microfluidic/microanalytical device may be 
realized. Researchers have highlighted, for example, the 
instability of the hepatocyte cell phenotype in vitro using 
conventional culture techniques. A three-dimensional tissue 
model will, in contraindication, foster retention of hepatocyte 
function [9].   
Furthermore, direct cell deposition offers tighter control 
over the spatial distribution of cells and doesn’t rely upon cell 
migration to populate the scaffold, allowing us to co-culture 
multiple cells types within a three-dimensional scaffold [10]. 
This can create tissue structures that more closely resemble 
their in vivo state. Just as with blood circulation in the whole 
animal model, metabolic regulations are set by reciprocal 
interaction between various organs via the microfluidic 
channels. 
Ultimately, the rationale for using a microscale animal-
on-a-chip device needs to be tenable. Among these are the 
ability to perform faster separations with no losses in 
separation efficiency, lower reagent and sample consumption, 
less waste production, and the unique ability and versatility to 
fabricate multiple and varied parallel systems on the same 
device. Further, fabricating tissue constructs with 3D 
architecture seems rational enough as organs appear in situ, 
but the emerging technologies that our lab implements makes 
it both feasible and reproducible. The confluence of 
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microfluidic technology and bioprinting 3D tissue capabilities 
will eventuate in microfabricated devices consisting of a 
fluidic network of channels biomimicking the human 
circulatory system and metabolic machinery to assist in 
prediction of human response to pharmaceutical therapy and 
potential toxins. 
 
II.   METHODS AND MATERIALS 
 
Mouse hepatocytes (ATCC, CRL-2254) were 
encapsulated within alginate hydrogels  and bioprinted 
through the system into a desired pattern within the 
microfluidic circuits. To develop a model drug system to 
demonstrate effective drug metabolism in the liver chamber, a 
non-fluorescent prodrug is fed into the system through the 
inlet port, metabolized by the liver chamber, and then 
produces an effluent fluorescent metabolite collected at the 
outlet port for subsequent analysis. A 3D sandwiched tissue 
construct is posited with a candidate drug completely 
circumscribed by alginate strands to realistically simulate the 
sinusoidal blood flow configuration in vivo as shown in Figure 
II. Further, we have optimized the cell-encapsulated alginate 
structure in order to accurately recapitulate the diffusive 
properties from the bloodstream to the target tissues by 
modeling the transport properties of the drugs through alginate 
strands. 
 
  
Figure I: Bioprinting System Figure II: Sandwiched Sinusoidal Construct 
 
III.   DESIGN FEATURES 
 
Our microfluidic device will be directly intergrated with 
the multiple 3-D tissue chambers forming a cohesive unit. The 
purpose of this device is to create an in-vitro system for 
studying the effects of drugs, drug metabolites, and drug-drug 
interactions on multiple tissues simultaneously. Further, these 
devices are envisioned for use in low-gravity space and 
planetary environments and on Earth.  
Preliminary testing has demonstrated good viability of a 
variety of encapsulated cells under different deposition 
conditions using live/dead assays (Figure III,IV,V).While the 
cells that we will primarily focus on are hepatocyte liver cells, 
we would also like to ensure a biofriendly environment for 
vascular endothelial cells and various other soft tissue 
parenchymal cells. Almar blue staining and cytofluorimetry 
will be used to determine cell proliferation during several 
weeks of incubation. Initial scaffold biomaterials for cell 
encapsulation will be alginate and fibrin. Further biological 
studies may include comparisons of the cellular response and 
morphology of the tissue constructs and natural tissue. One 
functional characterizing test for hepatocytes is the urea assay 
kit, which serves as a useful biochemical marker for assessing 
level of phenotype preservation. Structures at the tissue level 
will also be studied to see if the artificial tissue construct has 
the same higher-level organizational pattern as in vivo tissue.  
 
 
(a) 
 
(b) 
 
(c) 
Figure III(a-c): Bioprinted Tissue Constructs 
  
Figure IV: Live/Dead Assay indicates 
process viability 
Figure V: Hepatocyte Cell Viability 
Ratios 
 
Since hepatocytes are the cells that steward the metabolic and 
biosynthetic processes in the body, bioprinted liver tissue 
constructs will be a focal chamber and fixture in most of our 
microfluidic circuits. Subsequent metabolic and flow analysis 
will inform us as to the relative pharmacokinetic efficiency 
and relevancy of our microfabricated tissue-on-a-chip for 
human application.  
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